[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"zoster-associated-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:zoster-associated-pain":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100636768",false,"NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor","ALL","18 Years","85 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[27,28,29,30,31],"Herpes Zoster","Zoster-Associated Pain","Postherpetic Neuralgia","Neuropathic Pain","Acute Pain",[33,34,35,36,27,37,29,30,38,39,40],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Zoster Pain","Analgesia","Non-pharmacological Intervention","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-05",{"date":44,"type":45},"2026-05-08","ACTUAL",{"date":47,"type":21},"2026-05-01",{"date":49,"type":21},"2026-07-10",{"name":51,"class":52},"Nakhia Impex LLC","INDUSTRY",""]